Zura Bio Limited (ZURA)
NASDAQ: ZURA · Real-Time Price · USD
4.830
+0.030 (0.63%)
At close: May 14, 2026, 4:00 PM EDT
4.830
0.00 (0.00%)
After-hours: May 14, 2026, 6:03 PM EDT
Zura Bio Stock Forecast
Stock Price Forecast
The 6 analysts that cover Zura Bio stock have a consensus rating of "Buy" and an average price target of $13, which forecasts a 169.15% increase in the stock price over the next year. The lowest target is $2.00 and the highest is $18.
Price Target: $13 (+169.15%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 23, 2026.
Analyst Ratings
The average analyst rating for Zura Bio stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $10 → $11 | Strong Buy | Maintains | $10 → $11 | +127.74% | Mar 23, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $16 → $15 | Buy | Maintains | $16 → $15 | +210.56% | Mar 20, 2026 |
| Wedbush | Wedbush | Buy Initiates $15 | Buy | Initiates | $15 | +210.56% | Feb 9, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +107.04% | Nov 14, 2025 |
| Clear Street | Clear Street | Strong Buy Initiates $18 | Strong Buy | Initiates | $18 | +272.67% | Nov 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
10.93M
EPS This Year
-0.68
from -1.06
EPS Next Year
-0.63
from -0.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 78.8M | ||||||
| Avg | n/a | 10.9M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.49 | -0.12 | |||
| Avg | -0.68 | -0.63 | |||
| Low | -0.87 | -1.00 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.